Metabolic dysfunction, rather than steatotic liver disease (SLD), seems to be the main driver of chronic kidney disease (CKD) risk.

Topline 6-month pivotal data expected in early Q4 2026 with potential FDA marketing application submission expected in late Q4 2026Company ...

A new research paper was published in Volume 18 of Aging-US on February 6, 2026, titled "Causal effects of inflammation on long-term mortality: a Mendelian randomization study." ...

Intraoperative MRI-Guided Resection Is Not Superior to 5-Aminolevulinic Acid Guidance in Newly Diagnosed Glioblastoma: A Prospective Controlled Multicenter Clinical Trial This clinical trial's ...

In a setting where a 2:1 randomization requires a 1% larger sample size the duration of a survival trial would only be shortened by 9% to 8.2 years (relative to a 9-year 1:1 randomization trial ...

The genetic and clinical heterogeneity of breast cancer makes the identification of effective therapies challenging. We designed I-SPY 2, a phase 2, multicenter, adaptively randomized trial to screen ...